Sunosi (Solriamfetol)

Sunosi (solriamfetol) is a dopamine and norepinephrine reuptake inhibitor (DNRI) used to improve wakefulness in adult patients with excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA).

Limitations of Use:
This therapeutic drug does not treat airway blockage in OSA (Obstructive Sleep Apnea). Make sure to treat the airway obstruction first, like using CPAP, for at least 30 days before starting this medicine for daytime sleepiness. Continue using CPAP or other treatments while using Solriamfetol. This medicine is not a replacement for these treatments.

Recommended Dosage: The recommended dosage of Sunosiis administered orally upon awakening with or without food. Avoid taking dosage within 9 hours of planned bedtime because of the risk of interfering with sleep if taken too late in the day.

• Dosage in Narcolepsy: Start treatment at 75 mg once daily in adults with narcolepsy. The recommended dose range is 75 mg to 150 mg once daily. On behalf of the efficacy and tolerability, the dosage may be doubled at intervals of at least 3 days. The maximum recommended dose is 150 mg once daily. Dosages beyond 150 mg daily do not confer increased effectiveness sufficient to outweigh dose-related side effects.
• Dosage in OSA: In adults with OSA, start treatment at 37.5 mg once daily. The recommended dosage range is 37.5 mg to 150 mg once daily. For efficacy and tolerability, the dosage may be doubled at intervals of at least 3 days. The maximum recommended dosage is 150 mg once daily. Dosages beyond 150 mg daily do not confer increased effectiveness sufficient to outweigh dose-related side effects.

Using Solriamfetol 75 mg/150 mg might lead to an elevation of blood pressure and heart rate. It is advisable to monitor the blood pressure and heart rate regularly while using this medication. Any unusual symptoms such as headaches, dizziness, and chest pain should be reported to the healthcare provider promptly. Some changes in treatment may be necessary.
Patients taking Solriamfetol can develop anxiety, agitation, and other changes in their mood. Healthcare providers (HCPs) need to be notified if there is any drastic change in the general mood, behavior or thoughts of the patient. Medication in some cases would need to be stopped. New and worsening psychiatric problems should always be disclosed.
This therapeutic drug is contraindicated in pregnancy unless the situation is compelling. Animal studies suggest some risk to the fetus and there is very little human data. Speak to your healthcare provider (HCP) if you are pregnant or intend to become pregnant so that the benefits and risks can be analyzed.
There is no information regarding passage into breast milk hence caution is advised while taking Solriamfetol during breastfeeding. Consult with your healthcare provider if you are breastfeeding and thinking of taking this medicinal product. An alternative treatment option may be proposed, or the decision to cease breastfeeding may need to be made.
Under no circumstances should Solriamfetolbe combined with any form of monoamine oxidase inhibitors (MAOIs) due to the use of these medications together having severe side effects such as an increase in blood pressure. After you stop using an MAOI, you must wait at least 14 days before you can begin taking Solriamfetol.
If you are using any dopaminergic drugs, then Solriamfetol should be taken with caution as there is a risk of experiencing side effects such as hypertension or cardiovascular complications. Make sure to inform the physician of any using dopaminergic medications prior to using this medicine.

What documents are required to import SUNOSI to India?

SUNOSI (solriamfetol) tablets can be imported by patients or government hospitals in the patients' name only.

• The following documentation is required to import the product:
• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order be confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is SUNOSI available in India?

SUNOSI (solriamfetol tablet) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Sunosi in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

SUNOSI can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of SUNOSI (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Sunosi 75 mg/150 mg tablet price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source SUNOSI (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Sunosi®?

Solriamfetol is a Generic Name for the trade name drug Sunosi®.

What is the Manufacturer's Name of Sunosi®?

Sunosi® is manufactured by Axsome Therapeutics Inc.

Is Sunosi® approved by the FDA?

Yes, Sunosi® is approved by the FDA. Date of first approval: March 20, 2019.

What is the dosage and form of Sunosi® supplied?

Sunosi is supplied in Tablets: 75 mg (functionally scored) and 150 mg for oral administration.

What are the most common side effects of Sunosi®?

The most common side effects of Sunosi® are headache, nausea, insomnia, decreased appetite, and anxiety.

How much does the Sunosi® tablet cost in India?

Prices of Sunosi may fluctuate over time due to market dynamics and regulatory changes. To get the most accurate and latest details on Sunosi 75 mg/150 mg cost in India, please Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Sunosi® be available in SAARC countries?

Apart from Gulf countries, Sunosi® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Sunosi® tablets in these countries. We help ensure legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Sunosi® Tablets online in India?

Yes, one can buy Sunosi online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Sunosi® oral tablets through legal channels.

What are the storage conditions of Sunosi® 75 mg/150 mg tablets?

Store tablets at 20 to 25°C (68°to 77°F); excursions permitted between 15°to 30°C (59°to 86°F).